Screener
King Pharmaceuticals KG Acquisitions
Acquisitions at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAcquiredFromAcquisition.
The source filing: King Pharmaceuticals’s 10-K, filed March 13, 2026.
- Filed
- Mar 13, 2026, 8:06 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-017506
| For the Year Ended December 31, | 2025 | 2024 |
|---|---|---|
| Proceeds from sales of fixed maturities | 62,788 | — |
| Proceeds from maturities, paydowns and calls of fixed maturities | 85,202 | — |
| Proceeds from sale and redemption of other investments | 2,954 | — |
| Cash acquired from purchase of business | 79,807 | — |
| Net loan receivable from related party | 22,433 | — |
| Others, net | (21) | — |
| Net cash provided by investing activities | 146,945 | — |
| Cash flows from financing activities: |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is King Pharmaceuticals's acquisitions?
- King Pharmaceuticals (KG) reported acquisitions of $19.95M in Q4 2025.
- What does acquisitions mean?
- Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.
Ask your AI about King Pharmaceuticals's acquisitions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude